# The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes

Study · id `cardio:ct-nct05844644` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05844644](<https://clinicaltrials.gov/study/NCT05844644>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05844644

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05844644. Allocation not applicable; no masking; primary purpose treatment. Start 2023-04-20 (actual); primary completion 2024-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05844644, source copy `cardio:ctgov-nct05844644-2024-07-26`, retrieved 2026-10-26)
- Started: 2023-04-20 (actual) (ClinicalTrials.gov record NCT05844644, source copy `cardio:ctgov-nct05844644-2024-07-26`, retrieved 2026-10-26)
- Primary completion: 2024-11 (anticipated) (ClinicalTrials.gov record NCT05844644, source copy `cardio:ctgov-nct05844644-2024-07-26`, retrieved 2026-10-26)
- Completion: 2025-01 (anticipated) (ClinicalTrials.gov record NCT05844644, source copy `cardio:ctgov-nct05844644-2024-07-26`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT05844644, source copy `cardio:ctgov-nct05844644-2024-07-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05844644-2024-07-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes
- Condition: Type 2 Diabetes
- Condition: Obese
- Condition: Overweight
- Condition: Prediabetes
- Intervention (Dietary supplement): Release
- Lead sponsor: Golo
- Lead sponsor class: INDUSTRY
- Collaborator: KGK Science Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 45b6596e825cbf7ad01804358c585e19c6f2733233e8f7fbb697361d6bee8441
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
